メインコンテンツに移動する
JapaneseホームNewsホーム
Story
13/50

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib) - Johnson & Johnson

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib)  Johnson & Johnson J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso  Fierce Pharma Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications  Medical Professionals Reference U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer  Yahoo Finance Genmab partner gets FDA approval for expanded use of lung cancer drug  medwatch.com

Latest News